Chronic motor neuropathies: Response to interferon-β1a after failure of conventional therapies

Journal of Neurology Neurosurgery and Psychiatry

Volumn 66, Issue 2, 1999, Pages 197-201

  Martina, I S J ^a   Van Doorn, P A ^a   Schmitz, P I M ^a   Meulstee, J ^a   Van Der Meche F G A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic motor neuropathy; Interferon

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM1; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; DISABILITY; ERYTHEMA; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR NERVE BLOCK; MOTOR NEUROPATHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SWEATING; TREATMENT FAILURE; TREATMENT OUTCOME; WALKING;

EID: 0032961412     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.66.2.197     Document Type: Article

References (24)

1. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-8.
2. Kornberg AJ, Pestronk A. Chronic motor neuropathies: diagnosis, therapy, and pathogenesis. Ann Neurol 1995; (suppl 1):S43-50.
3. Oh SJ, Claussen GC, Odabasi Z, et al. Multifocal demyelinating motor neuropathy: pathologic evidence of inflammatory demyelinating polyradiculoneuropathy. Neurology 1995;45:1828-32.
4. Krendel DA. Biopsy findings link multifocal motor neuropathy to chronic inflammatory demyelinating polyneuropathy. Ann Neurol 1996;40:948-9.
5. Chaudry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: responsee to human immune globulin. Ann Neurol 1993;33:237-42.
6. van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-52.
7. Feldman EL, Bromberg MB, Albers JW, et al. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991;30:397-401.
8. Report from an adhoc subcommittee of the American Academy of Neurology AIDS task force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-8.
9. Mathiowetz V, Weber K, Kashman N, et al. Adult norms for the nine hole peg test of finger dexterity. Occupational Therapy Journal of Research 1985;5:24-38.
10. Collen FM, Wade DT, Bradshaw CM. Mobility after stroke: reliability of measures of impairment and disability. International Disability Studies 1990;12:6-9.
11. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
12. Kleyweg RP, van der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-9.
13. Jacobs BC, van Doorn PA, Schmitz PIM, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996;40:181-7.
14. Green WH. Econometric analysis, 2nd ed. New York: Macmillan, 1993.
15. Thompson N, Choudhary P, Hughes RAC, et al. A noval trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996;243:280-5.
16. Choudhary PP, Thompson N, Hughes RAC. Improvement following interferon β in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995;242:252-3.
17. Sabatelli M, Mignogna T, Lippi G, et al. Interferon-α may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathies [letter]. J Neurol Neurosurg Psychiatry 1995;58:638-9.
18. Mariette X, Chastang C, Clavelou P, et al. A randomised clinical trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 1997;63:28-34.
19. Gorson KC, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a. Neurology 1998;50:84-7.
20. van Doorn PA, Brand A, Strenger PFW, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled, crossover study. Neurology 1990;40:209-12.
21. Weinstock-Guttman B, Ransohoff RM, Kinkel P, et al. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
22. Noronha A, Toscas A, Jensen MA. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-54.
23. Pollard JD, McCombe PA, Baverstock J, et al. Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1986;13:123-34.
24. Lugaresi A, De Luca G, Iarlori C, et al. Interferon β normalizes suppressor cell function in dysimmune neuropathies [abstract]. J Neurol 1997;244:S66.